Participating Clinical Centers
Clinical Studies
5403: A Phase I/II Trial of Sirolimus (Rapamune®) and Cyclosporine in Patients with Refractory Aplastic Anemia
Status: Recruiting
Summary:
Please Note: The Rare Diseases Clinical Research Network will make every effort to enroll all the patients we can, but we cannot make any guarantees that we will be able to enroll everyone in a particular study who wants to participate.
This study will evaluate the safety and effectiveness of giving sirolimus in combination with cyclosporine to aplastic anemia patients.
Target Enrollment:
Patients with acquired moderate or severe aplastic anemia with bone marrow cellularity <25%, failure to respond durably to at least one course of ATG, and any of the pre-defined features at the time of the original diagnosis.
How to Participate:
In order to participate in a study, you must personally contact the study coordinator of any of the participating institutions by phone or by e-mail. Please use the information below to inquire about participation.
- Cleveland Clinic Foundation, Cleveland, OH
Susan Sunkle
216.445.2119
sunkles@ccf.org- University of California at Los Angeles, Los Angeles, CA
Troy Overfield-Blain
310.794.8075
toverfield@mednet.ucla.edu- H. Lee Moffitt Cancer Center, Tampa, FL
Lynn Tihopu
310.794.0738
Tihopu@mednet.ucla.edu
Join the Contact Registry: Aplastic Anemia
